Subject: (Copy) NIH Guide Vol. 18, No. 38, October 27, 1989, Part 1 (final,R
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Mon, 30 Oct 89 07:59 EST

Paul,
  This is the second article to be posted this morning.  Please
post it as NIHGUIDE.102789.
   Thanks and have a nice day.
                              Dottie
 ---------------------------- Text of forwarded message -----------------------
     
Subject: NIH Guide Vol. 18, No. 38, October 27, 1989, Part 1 (final,RFAs next)

     

     
     
Vol. 18, No. 38, October 27, 1989

                                   NOTICES

NEI INSTITUTIONAL TRAINING GRANTS .........................(84/104).......... 1
National Eye Institute
Index:  EYE

                     DATED ANNOUNCEMENTS (RFPs AND RFAs)

LARGE BOWEL ADENOMATOUS POLYP DIETARY INTERVENTION STUDY--
CLINICAL CENTERS (RFP) ....................................(110/145)......... 1
National Cancer Institute
Index:  CANCER

SUPPORT FOR "EMERGING TECHNOLOGY":  STUDIES ON THE AUGMENTATION OF
CELLULAR AND HUMORAL IMMUNE FUNCTION TO INCREASE THE PROTECTIVE
IMMUNE RESPONSE TO HIV INFECTION (RFP) ....................(161/199)......... 2
National Cancer Institute
Index:  CANCER

REAGENTS AND/OR SERVICES FOR AIDS VACCINE RESEARCH (RFP) ..(202/249)......... 2
National Cancer Institute
Index:  CANCER

STUDIES USING PRIMATES AND OTHER ANIMALS FOR AIDS VACCINE RESEARCH (RFP) .... 3
National Cancer Institute                                  (252/309)
Index:  CANCER

NATIONAL CANCER INSTITUTE COOPERATIVE HUMAN TISSUE NETWORK (RFA) ............ 4
National Cancer Institute                              (321/404, 724/1219)
Index:  CANCER

                        ONGOING PROGRAM ANNOUNCEMENTS

NUTRITION RESEARCH AND ORAL HEALTH .........................(410/552)........ 5
National Institute of Dental Research
Index:  DENTAL RESEARCH

NEUROSCIENCE RESEARCH ON DRUG ABUSE ........................(561/709)........ 7
National Institute on Drug Abuse
Index:  DRUG ABUSE

     

     

     

     

     

     

     
                                   NOTICES

NEI INSTITUTIONAL TRAINING GRANTS
     
P.T. 44; K.W. 0720005, 1014002
     
National Eye Institute
     
The National Eye Institute has recently revised its supplemental instructions
for institutional National Research Service Award applications.  NEI has only
one receipt date for these applications:  January 10 of each year.
     
Investigators are strongly encouraged to obtain a copy of these revised
instructions before submitting applications for the January 10, 1990 receipt
date.  Please contact:
     
Ralph J. Helmsen, Ph.D.
Research Training and Resources Officer
National Eye Institute
National Institutes of Health
Building 31, Room 6A46
Bethesda, Maryland  20892
Telephone:  (301) 496-5884

                     DATED ANNOUNCEMENTS (RFPs AND RFAs)

LARGE BOWEL ADENOMATOUS POLYP DIETARY INTERVENTION STUDY--CLINICAL CENTERS
     
RFP AVAILABLE:  NCI-CN-05220-20
     
P.T. 04; K.W. 0715035, 0705025, 0710095, 0755015
     
National Cancer Institute
     
The National Cancer Institute, Division of Cancer Prevention and Control, is
soliciting proposals for clinical centers to conduct a large bowel adenomatous
polyp dietary intervention study.  This multi-center randomized controlled
intervention study will examine the effect of a low-fat, high-fiber, vegetable
and fruit-enriched diet on the recurrence of adenomatous polyps of the large
bowel.  It is expected that an individual offeror will randomize participants
at a minimum rate of 7 per month, or 170 participants over the two-year
randomization period.  General requirements include identification and accrual
of eligible participants, nutritional education and counselling, participant
follow-up and endpoint assessment.  Intermediate endpoint specimens will be
collected.  Data maintenance and reporting quality control systems will be
supported.  A separate Request for Proposals (RFP) will be issued for a data
and nutrition coordinating center.
     
Date of issuance of the RFP will be approximately October 26, 1989, with a
closing date for receipt of proposals to be approximately January 4, 1990.
The Institute plans to award up to 12 contracts from this solicitation.
     
Copies of RFP No. NCI-CN-05220-20 may be obtained by sending a WRITTEN request
to:
     
Mr. Charles E. Lerner, Contract Specialist
National Institutes of Health
National Cancer Institute
Research Contracts Branch, PCCS
Executive Plaza South, Room 635
Bethesda, Maryland  20892
Telephone:  (301) 496-8603

     

     

     

     

                  Vol. 18, No. 38, October 27, 1989 - Page 1
SUPPORT FOR "EMERGING TECHNOLOGY":  STUDIES ON THE AUGMENTATION OF CELLULAR
AND HUMORAL IMMUNE FUNCTION TO INCREASE THE PROTECTIVE IMMUNE RESPONSE TO HIV
INFECTION
     
MASTER AGREEMENT ANNOUNCEMENT AVAILABLE:  NCI-CP-95666-45
     
P.T. 34; K.W. 0745045, 0715008, 0760080, 0740023
     
National Cancer Institute
     
The National Cancer Institute, Division of Cancer Etiology is soliciting
proposals from offerors with the capability to conduct Studies on the
Augmentation of Cellular and Humoral Immune Function to Increase the
Protective Immune Response to HIV Infection.  The successful offeror must be
able to develop procedures for immune therapy in HIV-infected human subjects
with purified HIV proteins and/or recombinant vector expressing HIV proteins.
     
The offeror must obtain consent and human subject protection certification;
furnish information on protocols used and results obtained; and provide
samples or serum and/or cells from the immunized subjects to NCI upon request.
     
It is anticipated that a Master Agreement Award will be made FOR A PERIOD OF
FORTY-EIGHT (48) MONTHS.  MASTER AGREEMENTS CONSIST OF A POOL OF PREQUALIFIED
OFFERORS.  After award, groups of Master Agreement holders will be invited to
propose competitively on Master Agreement Orders that will be designed to
accomplish a specific task to be designated by the Government.
     
Master Agreement announcement No. NCI-CP-95666-45 for the task described above
will be available to interested offerors on approximately October 21, 1989.
Responses will be due approximately 30 days after the publication date of this
announcement.  Copies of this RFP may be obtained by sending a written request
to:
     
Opal J. Bailey
Contract Specialist
Cancer Etiology Contract Section, Research Contracts Branch
National Cancer Institute
Executive Plaza South, Room 620
Bethesda, Maryland  20892

REAGENTS AND/OR SERVICES FOR AIDS VACCINE RESEARCH
     
MASTER AGREEMENT ANNOUNCEMENT AVAILABLE:  NCI-CP-95664-45
     
P.T. 34; K.W. 0715008, 0740075, 0780005, 0755041, 0755045, 0760060
     
National Cancer Institute
     
The National Cancer Institute, Division of Cancer Etiology, is soliciting
proposals from offerors with the capability to conduct Studies on Tasks A
through H listed below or on any combination thereof.  Separate, complete
proposals are required for each task.
     
Task A:  Protein Purification; Immunological Services, and
         Virus Detection and Isolation.
Task B:  Virus Production.
Task C:  DNA Sequencing.
Task D:  Molecular Cloning;  Production of Recombinant HIV,
         SIV, and/or EIAV proteins;  Production of recombinant
         vaccinia virus.
Task E:  Peptide Synthesis.
Task F:  Immunological Assays and Virus Characterization.
Task G:  PCR Analysis.
Task H:  Pathology.
     
It is anticipated that a Master Agreement Award will be made for a period of
forty-eight (48) months.  Master Agreements consist of a pool of prequalified
offerors.  After award, groups of Master Agreement holders will be invited to
propose competitively on Master Agreement Orders that will be designed to
accomplish a specific task designated by the Government.
     
Master Agreement announcement No. NCI-CP-95664-45 for the tasks described
above will be available to interested offerors approximately October 21, 1989.
Responses will be due approximately 30 days after the publication date of this
announcement.

     
                  Vol. 18, No. 38, October 27, 1989 - Page 2
Copies of the RFP may be obtained by sending a written request to:
     
Opal J. Bailey
Contract Specialist
Cancer Etiology Section
Research Contracts Branch
National Cancer Institute
Executive Plaza South, Room 620
Bethesda, Maryland  20892

STUDIES USING PRIMATES AND OTHER ANIMALS FOR AIDS VACCINE RESEARCH
     
MASTER AGREEMENT ANNOUNCEMENT AVAILABLE:  NCI-CP-95665-45
     
P.T. 34; K.W. 0715008, 0740075, 1002002
     
National Cancer Institute
     
The National Cancer Institute, Division of Cancer Etiology, is soliciting
proposals from offerors with the capability to conduct Task A, B, C-1, C-2 or
any combination listed below.  Separate proposals are required for each task
or subtask.
     
Task A:  Provide non-human primates and, housing, care and health surveillance
for these primates; immunize primates with SIV, HV-1 or HV-2 vaccines (to be
provided by NCI); infect primates with HIV or SIV vaccines and assess the
status of these immunized and infected primates; and conduct other
experiments.
     
Task B:  Provide, house, and care for severe combined immunodeficient (SCID)
mice; reconstitute these animals with human tissue to obtain lymhpoid and/or
cells which can be infected with HIV in the mice; develop methods to
reconstitute the mice with human immune cells; evaluate various antibodies;
and, if suitable systems are developed, conduct immunization in the human-SCID
mice and assess the response.
     
Task C-1:  Provide other animals and house and care for them; infect animals
with virus; determine the immune response; and re-isolate virus from tissues
of infected animals.
     
Task C-2:  Provide animals for immunogenicity studies; house and care for
these animals; immunize these animals, immunize these animals with candidate
vaccines; and provide NCI with sera and cells from immunized animals.
     
The offeror's facilities must conform to the standards for animal care
outlined in the Guide for care and Use of Laboratory Animals as published in
the DHHS publication Number (NIH 85-23) or superseding editions.
     
It is anticipated that a Master Agreement Award will be made for a period of
forty-eight (48) months.  Master Agreements consist of a pool of prequalified
offerors.  After award, groups of Master Agreement holders will be invited to
propose competitively on Master Agreement Orders that will be designed to
accomplish a specific task to be designated by the Government.
     
Master Agreement Announcement No. NCI-95665 for the tasks described above will
be available to interested offerors on approximately October 21, 1989.
Responses will be due approximately 30 days after the publication date of this
announcement.
     
Copies of the RFP may be obtained by sending a written request to:
     
Opal J. Bailey
Contract Specialist
Cancer Etiology Section
Research Contracts Branch
National Cancer Institute
Executive Plaza South, Room 620
Bethesda, Maryland  20850

     

     

     
     
                  Vol. 18, No. 38, October 27, 1989 - Page 3
NATIONAL CANCER INSTITUTE COOPERATIVE HUMAN TISSUE NETWORK
     
RFA AVAILABLE:  90-CA-01
     
P.T. 34, FF, II; K.W. 0780000, 0780020, 0715035
     
National Cancer Institute
     
Letter of Intent Receipt Date:  January 12, 1990
Application Receipt Date:  April 25, 1990
     
The Diagnosis Research Program of the Division of Cancer Biology and Diagnosis
at the National Cancer Institute (NCI) invites applications for Cooperative
Agreements from institutions capable of and interested in participating in The
Cooperative Human Tissue Network.  The purpose of this established network is
to collect and distribute human tumor tissue and normal tissue to stimulate
research.  The Network was developed in response to a growing need by
researchers for improved access to human tumor tissue.  Basic and
developmental studies in many areas of cancer research, including molecular
biology, immunology and genetics, have been encouraged by improved access to
tissue.  Hundreds of investigators have taken advantage of the existence of
the Network and thousands of tissues have been distributed since the inception
of the Network in January 1987.  The NCI plans expand the Network from three
institutions to four or five institutions.
     
The existing Network has already demonstrated the feasibility of the network
approach and the continuing need of researchers for access to human materials.
Systems have been developed that allow efficient communication among
laboratories regarding tissue requests and availability.  The Network is not a
tissue bank, but rather responds to investigator requests to meet existing
tissue requirements on a current basis.  Applicants may plan for limited
storage of rare tumors that would otherwise not be available.  Special
consideration will be given to ensuring access to and nationwide distribution
of rare pediatric tumor specimens.
     
Awards will be made as cooperative agreements which create an assistance
relationship with substantial involvement of NCI staff during the performance
of the project, as outlined in this request for applications (RFA).  This
mechanism is used when the NCI wishes to stimulate investigator interest and
proposes to advise or assist in an important and opportune area of research.
The NCI anticipates making four or five awards for project periods of five
years.  Although this project is provided for in the financial plans of the
NCI, the award of cooperative agreements pursuant to the RFA is contingent on
the availability of funds appropriated in fiscal year 1991.
     
Inclusion of women and minorities are encouraged.  If they are excluded,
reasons for this exclusion must be included in the application.
     
This RFA is a one-time solicitation with a specified deadline of April 25,
1990, for receipt of applications.
     
The RFA label available in the 10/88 revision of Application Form 398 must be
affixed to the bottom of the face page.  Failure to use this label could
result in delayed processing of your application such that it may not reach
the review committee in time for review.  In addition, the RFA number and
title should be typed on line 2 of the face page of the application form.
     
A copy of the complete RFA describing eligibility criteria, the research goals
and scope, the cooperative agreement mechanism, the review criteria and the
method of applying should be obtained before beginning the application
process.  Copies of the complete RFA can be obtained from:
     
Roger L. Aamodt Ph.D.
Program Director for Pathology and Cytology
Diagnosis Program
Division of Cancer Biology and Diagnosis
National Cancer Institute
Executive Plaza South, Room 638
6120 Executive Boulevard
Rockville, Maryland  20892
Telephone:  (301) 496-7147
     
Inquiries concerning this RFA are encouraged and should be directed to Dr.
Aamodt at the address or telephone number listed above.
     
This program is described in the catalog of Federal Domestic Assistance no
13.394, Cancer Detection and Diagnosis Research.  Awards are under
authorization of the Public Health Service Act, Title IV, Part A (Public Law
     
                  Vol. 18, No. 38, October 27, 1989 - Page 4
78-410 as amended:  42 USC 241) and administered under PHS grant policies and
Federal Regulations 42 CFR Part 52 and 45 CFR Part 74.  This program is not
subject to the intergovernmental review requirements of Executive Order 12372
or Health Systems Agency review.

                        ONGOING PROGRAM ANNOUNCEMENTS

NUTRITION RESEARCH AND ORAL HEALTH
     
P.T. 34; K.W. 0710095, 0715148, 0755020, 0785055, 0710030
     
National Institute of Dental Research
     
The National Institute of Dental Research (NIDR) encourages submission of high
quality applications for the support of research and research training on the
influence of diet and nutrition on oral health and disease, salivary gland
function, craniofacial development, osteoporosis as related to craniofacial
structures, and wound healing in order to expand its activities in these and
other related areas.  Appropriate studies might encompass basic research,
development of animal models, epidemiological studies, and clinical studies of
special population groups, including the aged and minorities and those in
foreign countries which present special research opportunities.
     
BACKGROUND
     
The oral cavity and associated structures are the sites of disease (e.g.,
dental caries, periodontal disease, herpes, salivary gland disorders, oral
cancer) and congenital anomalies (such as cleft lip and palate) that may
relate to nutritional status.  It is also evident that nutrients interact with
physiologic systems in the oral cavity such as host and microbial cell
replication mechanisms, host cell repair mechanisms and immune response
mechanisms in such a manner as to increase or decrease the risk of disease and
influence tissue development.  Thus, the oral tissues and associated
structures constitute a major site of interactions between nutritional factors
and physiological systems, a relationship that makes oral health no less
vulnerable to the effects of nutrition than general health.
     
Expansion of the NIDR Nutrition Research Program was recommended by expert
panels on Long-Range Research Plans for the 1990's, at a recent Workshop on
International Collaboration for Oral Research, and by the Dental Research
Programs Advisory Committee (PAC) at its November 1988 meeting.  The PAC
recommended the issuance of a Program Announcement to encourage the needed
research and training in this area.
     
RESEARCH GOALS
     
The objective of this announcement is to solicit applications for research
grants and individual research training to elucidate the role of diet and
nutrition in the development and maintenance of oral and craniofacial tissues
and in the prevention of oral diseases.  Projects concerning nutrition and
oral health and disease as related to minorities, women, and the elderly and
to populations in developing countries which present special research
opportunities (via international collaboration) are
encouraged.  Examples of research projects are:
     
  o  Influence of nutrient-drug interactions on specific salivary gland
     structure and functions in the elderly.
     
  o  Relationship between nutrient intake during critical periods of
     gestation and susceptibility to craniofacial anomalies.
     
  o  Effect of malnutrition on abnormal tooth development or on
     osteoporosis of the jaw bone.
     
  o  Effect of sugar substitutes and food additives on the physiology of
     cariogenic bacteria and on dental caries.
     
  o  Bioavailability and mineralized tissue effects of fluoride in
     nutritionally compromised individuals.
     
  o  Preventive role of antioxidant nutrients in diseases of the
     periodontium or of the oral mucosa.
     
The above list is not intended to describe the full range of possible
activities to be supported nor to direct applicants to these areas.  Applicant
institutions are encouraged to focus on their areas of greatest strength.
     
                  Vol. 18, No. 38, October 27, 1989 - Page 5
The announcement is also intended to:  encourage increased collaboration among
the various disciplines of dental research involving nutrition and among basic
and clinical scientists; encourage training of basic and clinical research
scientists in oral nutrition; and expedite the translation of advances in
nutrition/oral biology research into new and improved methods for patient
care.
     
MECHANISMS OF SUPPORT
     
Support for this program will be through regular research project grants
(R01), program project grants (P01), small grants (R03), FIRST awards (R29),
AREA awards (R15), career development awards (K04, K11, K15), and postdoctoral
fellowships (F32, F33).  Receipt dates and policies that govern research grant
programs of the National Institutes of Health will prevail.
     
APPLICATION AND REVIEW PROCEDURES
     
Applications in response to this announcement will be reviewed on a nationwide
basis in competition with other applications and in accordance with NIH peer
review procedures.  Review criteria include:  the significance and originality
of the research goals and approaches; feasibility of the research and adequacy
of the experimental design; training, experience, research competence, and
dedication of the investigator(s); adequacy of available facilities and
availability of appropriate study populations; provisions for the protection
of human subjects and humane care of animals; and appropriateness of the
requested budget relative to the work proposed.  Applicants are encouraged to
include women and minorities in clinical and epidemiological studies.  For
studies which exclude women or minorities, a clear rationale for exclusion
should be provided.
     
Funding decisions will be based on the Study Section's and the National
Advisory Council's recommendations regarding scientific merit and program
relevance, and on the availability of appropriated funds.
     
Inquiries concerning this announcement should be addressed to Dr. Joseph E.
Ciardi at the address given below.  The specific application forms and kits
required to respond to this announcement are available from the institution's
Office of Research and Sponsored Programs or from the Division of Research
Grants, NIH.  Applications will be accepted on an indefinite basis in
accordance with the receipt dates specified in the pertinent application kits.
     
The phrase "NIDR PA:  NUTRITION RESEARCH AND ORAL HEALTH" should be typed on
line 2 of the face page of the application form PHS 398 (rev.  10/88) or on
line 3 of the fellowship application form PHS 416 (rev.  7/88).  The original
and six copies should be sent or delivered to:
     
Grants Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, Maryland  20892-4500**
     
For further information concerning this announcement and the mechanisms of
support for research and training available in this connection, applicants are
encouraged to contact:
     
Joseph E. Ciardi, Ph.D.
Program Administrator
Caries, Restorative Materials
  and Salivary Research Branch
Extramural Program
National Institute of Dental Research
Westwood Building, Room 505
Bethesda, Maryland  20892-4500
Telephone:  (301) 496-7884
     
This program is described in the Catalog of Federal Domestic Assistance No.
13.121, Diseases of the Teeth and Supporting Tissues.  Awards will be made
under authorization of the Public Health Service Act, Title III, Section 301
(Public Law 78-410, as amended; 42 USC 241); and administered under PHS grants
policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74.  This
program is not subject to the intergovernmental review.

     

     
     
                  Vol. 18, No. 38, October 27, 1989 - Page 6
NEUROSCIENCE RESEARCH ON DRUG ABUSE
     
P.T. 34; K.W. 1002030, 0404009, 0705055, 0760075, 0414005, 0404000, 0785115
     
National Institute on Drug Abuse
     
This Program Announcement was published in the NIH Guide for Grants
and Contracts on October 20, 1989, Vol. 18, No. 37, however, it was
inadvertently omitted in the Table of Contents.  The Announcement is
being repeated in its entirety.
     
PURPOSE
     
The purpose of this announcement is to encourage and stimulate investigator
interest in broad areas of neuroscience research relevant to the problem of
drug abuse.  Many research tools are now available to allow for major advances
in understanding the neurobiology of drug abuse to determine the effects of
drugs on the structure and function of the nervous system.  These include new
histochemical and autoradiographic procedures, light and electron microscopic
analysis, imaging and analytic techniques applicable to living tissue (e.g.,
PET, MRI), and various neurophysiological and neuropharmacological techniques,
especially those monitoring neural processes during ongoing behavior (e.g.,
single-cell electrophysiology, in vivo microdialysis and voltammetry, evoked
potentials, EEG).  As a final part of this initiative, The National Institute
on Drug Abuse (NIDA) expects that an increased understanding of the
relationship between brain anatomy, physiology, and pharmacology and drug
abuse behaviors will increase the capacity to design appropriate therapeutic
pharmaceuticals void of abuse liability and its consequences, and develop drug
therapies for correcting neurochemical imbalances created by the abuse of
drugs.  Additionally, investigations into the neural basis of drug seeking
should identify those neurobiological factors that make an individual
vulnerable to the abuse of drugs.
     
RESEARCH OBJECTIVES
     
The neuroscience program of the NIDA's Division of Preclinical Research
encourages investigations into the basic mechanisms underlying the action of
abused drugs and substances on the central nervous system as well as research
leading to the development of drugs that potentially may be used on the
relationship between drug-receptor interactions or neurochemical alterations
and consequences of drug usage in terms of behavioral processes is
specifically encouraged.  Areas of particular interest include the following:
     
(1)  Brain Reward Mechanisms in Drug Abuse
(2)  Neuropsychopharmacology of Abused Drugs
(3)  Anabolic Steroid Abuse
(4)  Drug-Induced Neurotoxicity
(6)  Developmental Neurobiology
(7)  Drug Effects on Cognitive Processes
(8)  Drug Effects on Sensory Processes
(9)  Blood-Brain Barrier Studies
(l0) Clinical Neuroscience
     
Support can be obtained in the form of R01 (Research Project Grants), R03
(Small Grants), R13 (Research Conference Grants), and R29 (First Independent
Research Support and Transition Awards).
     
NIMH and various NIH Institutes have specific programs in the neurosciences.
Grant applications will be assigned to the appropriate Institute based upon
existing programmatic guidelines.
     
ELIGIBILITY
     
Applications may be submitted by public or private nonprofit or for-profit
organizations such as universities, colleges, hospitals, laboratories, units
of State or local governments, and eligible agencies of the Federal
government.  Women and minority investigators are encouraged to apply.
     
APPLICATION PROCEDURES AND RECEIPT SCHEDULE
     
State and local government agencies may use form PHS 5161-1 (rev.  11/88).
All other applicants should use the research grant application from PHS 398
(rev.  10/88).  The title of this announcement "NEUROSCIENCE RESEARCH ON DRUG
ABUSE" should be typed in item number 2 on the face page of the PHS 398
application form or in item 9 on the PHS 5161-1.
     
Application kits containing the necessary forms and instructions may be
obtained from business offices or offices of sponsored research at most
     
                  Vol. 18, No. 38, October 27, 1989 - Page 7
universities, colleges, medical schools, and other major research facilities.
If such a source is not available, the following office may be contacted for
the necessary application material:  Grants Management Branch, NIDA, Parklawn
Building, Room 10-25, 5600 Fishers Lane, Rockville, Maryland 20857.
     
Applications received under this announcement will be assigned to an initial
review group (IRG) in accordance with established PHS Referral Guidelines.
The IRGs, consisting primarily of non-Federal scientific and technical
experts, will review the applications for scientific and technical merit.
Notification of the review recommendations will be sent to the applicant after
the initial review.
     
Applications will receive a second-level review by an appropriate National
Advisory Council whose review may be based on policy as well as scientific
merit considerations.  Only applications recommended for approval by the
advisory council may be considered for funding.
     
The signed original and six (6) permanent, legible copies of the completed
application (original and two copies, if using PHS 5161-1) should be sent to:
     
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, Maryland  20892**
     
Receipt of         Initial           Advisory Council    Earliest
Applications       Review               Review          Start Date
     
February 1         June/July            Sept/Oct         December 1
June 1             Oct/Nov              Jan/Feb          April 1
October 1          Feb/March            May/June         July 1
     
Applications submitted in response to this Announcement are not subject to the
intergovernment review requirements of Executive Order 12372, as implemented
through Department of Health and Human Services regulations at 45 CFR Part 100
and are not subject to Health Systems Agency review.
     
REVIEW CRITERIA
     
Criteria for scientific/technical merit review of regular research grant
applications will include the following:  significance and originality from a
scientific and technical standpoint of the goals of the proposed research;
adequacy of the methodology proposed to carry out the research; qualifications
of the Principal Investigator and other key research personnel; availability
of adequate facilities, other resources, and collaborative arrangements
necessary for the research, appropriateness of budget estimates for the
proposed research activities, and adequacy of provisions for the protection of
human subjects and welfare of animals subjects as applicable.
     
FURTHER INFORMATION
     
Further information and consultation on program requirements relevant to
neuroscience research inquiries can be obtained from:
     
Dr. Roger Brown
Neuroscience Research Branch
National Institute on Drug Abuse
Parklawn Building, Room 10A-31
5600 Fishers Lane
Rockville, Maryland  20857
Telephone:  (301) 443-6975
     
FOOTNOTE:  This program is described in the catalog of Federal Domestic
Assistance No. 13.279.  Grants will be awarded under the authority of Section
301 of the Public Health Service Act, as amended (42 USC 241) and administered
in accordance with the PHS Grants Policy Statement and Federal regulations at
42 CFR Part 52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review.

**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE
CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH.  APPLICANTS WHO
USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S
REQUIREMENTS FOR SHOWING A STREET ADDRESS.  THE ADDRESS FOR THE WESTWOOD
BUILDING IS:  5333 Westbard Avenue
              Bethesda, Maryland 20816
     
                  Vol. 18, No. 38, October 27, 1989 - Page 8